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Abstract 
Schizophrenia is a common mental illness resulting from a complex interplay of genetic 
and environmental risk factors. Establishing its primary molecular and cellular 
aetiopathologies has proved difficult. However, this is a vital step towards the rational 
development of useful disease biomarkers and new therapeutic strategies. 
The advent and large-scale application of genomics, transcriptomics, proteomics and 
metabolomics technologies is generating datasets required to achieve this goal. This 
discovery phase, typified by its objective and hypothesis-free approach, is described in 
the first part of the review. The accumulating biological information, when viewed as a 
whole, reveals a number of biological process and subcellular locations that contribute to 
schizophrenia causation. The data also show that each technique targets different 
aspects of central nervous system function in the disease state. 
In the second part of the review, key schizophrenia candidate genes are discussed more 
fully. Two higher order processes, adult neurogenesis and inflammation, that appear to 
have pathological relevance, are also described in detail. 
Finally, the review discusses three areas where progress would have a large impact on 
schizophrenia biology: deducing the causes of schizophrenia in the individual, explaining 
the phenomenon of cross-disorder risk-factors, and distinguishing causative disease 
factors from those that are reactive or compensatory.  
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“One may speculate about some far future in which individuals will routinely undergo 
‘genic analysis’, as nowadays they are routinely vaccinated….Perhaps massive genic 
analysis of the population will eventually give us the information that will lead to working 
out the physical basis for mental disease.” 
Isaac Asimov 
The Genetic Code (1962) 
Publ. The New American Library, Inc. 
 
 
Introduction 
Schizophrenia is a chronic and severe mental illness defined by the presence of 
delusions and hallucinations (positive symptoms), apathy and social withdrawal 
(negative symptoms), and specific cognitive failures (Ref. 1). It is diagnosed through 
qualitative assessment of patient interview and case notes with reference to an agreed 
set of classification criteria. The absence of objective biological tests for schizophrenia 
(for example, through blood sample analysis or physiological readout) are a hindrance to 
disease prediction, diagnosis, therapeutic assessment and scientific research. The 
intangibility of the diagnosis results from the difficulties in assessing the living brain in 
conjunction with the substantial heterogeneities in biological origin and clinical 
presentation of the disorder.  
In this regard, a detailed description of the biology of schizophrenia would be invaluable. 
Traditionally, such a description has been based on three principal observations. Firstly, 
there is the pharmacologically defined involvement of specific neurotransmitter receptor 
systems and their particular anatomical pathways in the brain. The action of 
amphetamine in inducing or worsening psychotic symptoms suggested that 
dopaminergic hyperactivity is an important component of illness. Further elucidation of 
the key dopaminergic tracts in the brain affected by receptor-blocking antipsychotic 
medication explained both the alleviation of positive symptoms as well as motor-control 
side-effects. Hypofunction of the glutamatergic neurotransmitter system is also 
implicated through the action of neurotransmitter receptor antagonists such as PCP and 
ketamine, together with expression studies that show reduced subunit expression in post 
mortem brain samples from individuals diagnosed with schizophrenia (Ref. 2). Secondly, 
evidence from brain imaging approaches has provided evidence for regional brain 
abnormalities in structure – implicating neurodevelopment – and function associated with 
illness. Some of these features correlate with genetic risk status, as recently reviewed 
(Ref. 3). Thirdly, particular cellular pathologies in have been described in brains from 
patients diagnosed with schizophrenia: for example, reduced oligodendrocyte number 
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(Ref. 4) or altered neuronal cytoarchitecture (Ref. 5). Until recently, these ‘high-level’ 
observations, while highly informative, have not been matched by an understanding of 
the underlying genetic and molecular mechanisms. 
Schizophrenia is partly genetic (Ref. 6, 7, 8, 9) although its ‘genetic architecture’ (how 
many and what type of mutations contribute to illness in the individual and population) is 
still a subject of much debate (Ref. 10). The existence of families with a high density of 
affected individuals suggests that segregating unitary gene effects can strongly 
predispose to illness. However, not all diagnosed individuals show such inheritance 
patterns indicating that common, small-effect variants in multiple genes, co-occurring 
through random and transitory co-segregation, are able to produce a form of the disorder 
phenotypically indistinguishable from the familial. Evidence from epidemiology (Ref. 11) 
and the genomic studies described below suggests that certain genes are risk factors 
not only for schizophrenia, but also for bipolar disorder (Ref. 12, 13) and major 
depression (Ref. 14), hinting at a degree of biological overlap.  
In the eight years since the genetics of schizophrenia were last reviewed in this journal 
(Ref. 15), research in the field has been transformed in direction and ambition by the 
advent of ‘whole genome’ technologies, revealing the common genetic variation and rare 
DNA copy number variants (CNVs) that contribute to risk of illness. In parallel, the use of 
structural and functional brain imaging, bio-marker discovery through transcriptomics 
and proteomics, and the generation of several mouse disease models, is increasing our 
understanding of how primary biological deficits are translated into clinical outcome (Ref. 
16, 17, 18, 19, 20, 21). This review sets out the major discoveries from such studies – 
primarily those at the molecular and cellular end of brain functional hierarchy. While a 
broad but shallow approach is inevitable, there is a clear intention to highlight findings 
spanning research strategies and to discuss those techniques that perhaps do not 
currently receive the attention that they merit. With that in mind, the review covers paths 
to discovery, notable gene candidates, emerging processes, and ends with a discussion 
of three issues facing the field of schizophrenia research. Key reviews have been 
signposted throughout to allow the reader to explore specific aspects in more detail.  
 
The discovery process 
 
Genome-wide association studies 
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The genetic information responsible for the development and regulation of the brain is 
the foundation of its functional operation. This position suggests that genetic studies are 
the most likely to reveal primary and causative factors predisposing to illness. Case-
control association studies reveal the contribution of common genetic variation to risk of 
disease. The last 5 years have seen impressive progress following the move away from 
small, gene-specific studies towards the large genome-wide association studies 
(GWAS). These have been made possible by the sharing of DNA samples within 
consortia and the technological advances in the massively parallel detection of single 
nucleotide polymorphisms (SNPs) that make up the greater part of common variation. 
The GWAS experimental design makes no subjective assumptions concerning gene 
candidacy or even genic contribution (the studies include SNPs in gene-poor regions of 
the genome). This feature – along with the cytogenetic approaches detailed below - will 
probably do most to benefit the biological understanding of schizophrenia as it has 
bypassed the subjective and cyclical knowledge that drove much earlier individual 
genetic and biological studies. Numerous individual studies and some combined meta-
analyses (Ref. 22, 23, 24, 25, 26, 27, 28, 29, 30) have been carried out for 
schizophrenia – the latter intended to boost signal-to-noise ratio resulting from locus and 
allelic heterogeneity. A current estimate places the genetic contribution of common 
polymorphic variation to risk of schizophrenia at ~34% (Ref. 25). 
Identified genes have been subjected to specific replication studies as well as 
examination in related conditions such as bipolar disorder and major depression. The 
major confirmed finding is the association of schizophrenia with a broad swathe of 
markers on chromosome 6p22.1 (Ref. 25, 26, 27). This locus houses the Major 
Histocompatability Complex (MHC) consisting, in part, of the Human Leukocyte Antigen 
(HLA) genes that mediate the body’s monitoring of self and non-self in the context of 
infection. The potential role of the immune system in psychiatric disorder aetiology 
makes this an important finding and is discussed in more detail later. However, a note of 
caution must be attached to the finding. The MHC region is highly mutable, subject to 
strong natural selection, and known to influence mammalian mate choice. These are 
features all known to perturb the Hardy-Weinberg Equilibrium of allele frequencies in 
populations. Careful analysis will be required to ensure that the GWAS signals detected 
here are specifically attributable to influence on schizophrenia risk. Aside from the MHC 
genes, the associated region also contains a number of other genes including NOTCH4, 
a previously identified candidate gene with a neurodevelopmental role (Ref. 31), and a 
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histone gene cluster. We have recently shown that the histone cluster is co-ordinately 
regulated by the transcription factor SOX11 responsible for neuronal differentiation (Ref. 
32) suggesting that chromatin modification might be an alternative biological explanation 
for the association. 
Aside from the MHC region, GWAS studies have highlighted variants strongly linked with 
risk of schizophrenia within the following individual genes: ZNF804A, MYO18B/ADRBK2, 
AGAP1 (CENTG2), NTRK3, EML5, ERBB4, NRGN, TCF4, CCDC60, RBP1, PTPN21, 
CMYA5, PLAA, ACSM1, ANK3, SULT6B1, ASTN1, CNTNAP1, and GABRR1. Using an 
additional criterion of independent identification in at least two studies (including those 
also targeting bipolar disorder (Ref. 12)), the following genes may also be associated: 
ASTN2, OPCML, PSD3, RYR3, TMCC2, GRID1, A2BP1, CACNA1C, CNTN5, CRYBB1, 
EML5, CSMD1, FAM69A, LRP8, PTPRG1, SLIT3, TMEM17, and VGCNL1/NALCN. As 
further GWAS studies and meta-analyses amass (including those from non-Northern 
European populations) and cross-diagnostic comparisons are made, this list will slowly 
evolve into a robust set of candidates. A range of statistical methodologies and gene 
categorisation resources are now being leveraged to translate GWAS data into 
associated gene functions in order to define key biological processes perturbed in 
schizophrenia (Ref. 33). One study of gene functions enriched in single schizophrenia 
GWAS identified glutamate metabolism, apoptosis, and inflammation/immunity as major 
processes (Ref. 34). Another report found significant over-representation of cell 
adhesion molecules in two schizophrenia GWAS studies and moderate evidence in 
support of tight junction, cell cycle, glycan synthesis and vesicle transport pathways 
(Ref. 35). 
The extraction of biological pathway information from GWAS data will always be 
tempered by the fact that common variant frequencies have been modulated by ancient 
founder effects, selection pressures, and the migratory history of human populations. 
These geographical and pathological filters may limit the ability of GWAS to signpost the 
full range of genes and processes that underlie schizophrenia. 
 
Copy number variation and other cytogenetic failings 
Deviations from diploid copy number in the genome have been long recognised – 
particularly in the context of the duplications and deletions observed in cancer – but the 
full extent of copy number variants (CNVs) in humans has only been appreciated 
relatively recently (Ref. 36, 37, 38). In contrast to common SNPs, common CNVs do not 
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seem to predispose to disease risk (Ref. 39). Therefore the focus has been to identify 
rare CNVs enriched in, or specific to, schizophrenia (Ref. 40, 41, 42). As a 
consequence, the chief issue has therefore been how to statistically prove a causative 
role to a given rare CNV in a numerically limited sample set. Five properties of the CNVs 
discovered in schizophrenia are important to highlight. Firstly, CNVs appear largely 
randomly throughout the genome. They can be sporadic (clearly observed in autism) or 
(perhaps subsequently) present as familial forms. Hence, compared to common SNPs, 
CNVs may define a broader gene contribution to illness given sufficient sample size. 
Secondly, both deletions and duplications have been observed at specific loci in 
schizophrenia. This implies that copy number deviation, rather than direction of change, 
is the chief mediator of disease – a finding that holds true for other disorders and 
testifies to the subtleties of evolved gene expression regulation (Ref. 43). Thirdly, 
several very large CNVs that simultaneously alter the dosage of multiple genes, 
including those found at 1q21.1, 2q12, 3q29, 7q36.3, 15q13.3, 16p11.2 16p13.1, 17q12, 
and 22q11.2, are repeatedly and consistently over-represented in schizophrenia (Ref. 
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54). Among these, the 22q11.2 CNV represents a 
sub-microscopic version of the previously described chromosome 22 deletion that 
underlies velo-cardio-facial syndrome (VCFS)/DiGeorge syndrome - the most common 
genetically-defined risk factor for schizophrenia. A considerable challenge will be to 
dissect these ‘syndromic’ CNVs and expose the relative contribution of each constituent 
gene to the final clinical diagnosis. Fourthly, certain CNVs (particularly larger ones) 
initially linked to schizophrenia also contribute to the risk of other diagnoses such as 
autism spectrum disorder, developmental delay, mental retardation and epilepsy. The 
most convincing explanation for this observation is that these CNVs perturb brain 
development; an effect that is compounded by other gene variants (as a ‘second hit’ 
(Ref. 55)) or by the environment to define the precise clinical endpoint. The earlier 
observation of increased frequency and heritability of schizophrenia in individuals 
diagnosed with mental retardation can also be explained by the same 
neurodevelopmental model (Ref. 56). Finally, the degree to which CNVs contribute to 
the general risk of bipolar disorder is still uncertain (Ref. 39, 57, 58), but appears less 
than for schizophrenia. However, CNVs are associated with early-onset bipolar disorder 
supporting the notion that CNVs are strongly linked to the kind of neurodevelopmental 
dysfunction that may be a distinguishing feature of schizophrenia. 
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Small CNVs present an opportunity to identify individual candidate genes. The following 
is an non-exhaustive list of genes occurring in at least two schizophrenia CNV studies: 
A2BP1, ACP6, BCL9, CHD1L, CHRNA7, CLDN5, CNTNAP2, DLG2, FHIT, FLJ39739, 
FMO5, GJA5, GJA8, GNB1L, KLF13, NRXN1, PARK2, PRKAB2, TRPM1 and VIPR2. 
Additionally, the following genes show overlap between schizophrenia and bipolar 
disorder CNV studies: GRM7, LARGE, PTPRD, RTN4R, SNAP29, SOX5, TXNIP, 
UFD1L, and ZNF74. Generally, genes within CNVs associated with schizophrenia are 
statistically over-represented with functions relating to neurodevelopment, synaptic 
transmission, and signal transduction. 
An older form of cytogenetic investigation based on microscopic study of patient 
chromosome rearrangements has been productive in the search for schizophrenia risk 
genes in individuals and families (Ref. 59). Chromosomal disruption can sometimes be 
localised within specific genes that immediately become strong candidates for disease 
causation. A notable example is the study of a t(1;11) translocation disrupting the DISC1 
(disrupted in schizophrenia) gene in a Scottish family (Ref. 60, 61, 62, 63). Importantly, 
the large family size not only allowed the translocation to be statistically linked with 
illness but also allowed the detailed phenotypic assessment of family members – 
including the observation that diagnosis-free obligate carriers of the translocation 
nevertheless possessed measurable deficits in cognitive endophenotypes (Ref. 64, 65). 
It can be speculated that in these individuals the primary neurodevelopmental deficit is 
quantifiable but has not been matched by additional genetic or environmental factors 
required to cross a threshold into illness. Another gene, PDE4B, disrupted in an 
independent translocation event associated with schizophrenia, encodes a 
phosphodiesterase enzyme subsequently shown to bind to DISC1, thus providing a 
good example of functional convergence (Ref. 66). 
Other candidate schizophrenia genes identified via the cytogenetic route include a 
glutamate metabolism pathway enzyme, PSAT1  (Ref. 67), a kainate type ionotropic 
glutamate receptor, GRIK4/KA1 (Ref. 68, 69, 70), a member of the ATP-binding cassette 
membrane transporter family, ABCA13, (see section of rare variants below and (Ref. 
71)) and a brain transcription factor, NPAS3 (Ref. 72, 73, 74). The last of these has also 
been identified as a moderately significant risk factor for schizophrenia, bipolar disorder 
and major depression through GWAS analysis (Ref. 14, 75).  
 
Rare gene sequence variants in schizophrenia 
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The field awaits data from the final stage in genome-wide data gathering – the high 
throughput sequencing methodologies targeting rare variants in individual patients. A 
recent study has suggested that rare sequence variants are likely to contain a 
disproportionate number of non-synonymous pathological changes – a consequence of 
continuing negative selection pressure in the population (Ref. 76). However, the 
observation that the sequenced exomes of nominally healthy individuals reported to date 
all show multiple rare and apparently disruptive coding variants strongly predicted to 
cause illness is an indication that caution is warranted (Ref. 77). This reduced 
penetrance/compensation is likely to make rare variant confirmation statistically 
challenging. To date the analysis of rare variants associated with schizophrenia has 
largely been carried out on a gene-by-gene basis with conventional sequencing 
methodology. DISC1 (Ref. 78), ABCA13 (Ref. 71), KIF17 (Ref. 79), and PCM1 (Ref. 80) 
are examples of candidate genes that have been sequenced in case and control 
populations leading to the discovery of rare variants. Some of the variants – even those 
with clear impact on protein structure and function - have failed replication (Ref. 81). The 
whole genome and exome projects for schizophrenia will provide a clearer picture of the 
overall disease risk from rare variants – and reveal the extent of incomplete penetrance. 
 
Transcriptomic studies 
In contrast to primary genetic defects, the following three sections concentrate on the 
assessment of cellular activity and reactivity. Post-mortem gene expression studies have 
compared gene transcription between brain tissue samples taken from healthy control 
individuals and those from individuals diagnosed with schizophrenia. Originally, this was 
undertaken on a hypothesis-driven, gene-by-gene basis: for example, studying 
glutamate receptor expression changes in the schizophrenic brain (Ref. 82, 83, 84). The 
availability of full gene-set microarray chips has widened the search to reveal novel 
diagnostic biomarkers (Ref. 85, 86) as well as the gene ontologies (descriptors of 
biological function or location) significantly contributing to the pathology and aetiology of 
disease (Ref. 87). 
However, many extraneous factors modify expression profiles including response to 
drug treatment, age, gender and physiological state of the individual at death, the cell-
type complexity of the tissue excised for analysis and the preservation of the tissue post 
mortem. Additionally, there is uncertainty whether transcriptional changes reflect cause 
(which itself will be of heterogeneous nature between individuals) or a secondary 
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response to the disease state. With the adoption of large sample sets and best 
technical/analytical practice, the results from microarray studies have shown some 
convergence on particular biological processes. These include metabolic regulation, 
mitochondrial activity, synaptic function, inhibitory neurotransmission, oligodendrocyte 
and myelination processes, ubiquitin–proteasome function, chaperone function, and 
immune response. These are reviewed in detail elsewhere (Ref. 88, 89, 90, 91, 92, 93, 
94). Reduced brain expression of RGS4 (regulator of G-protein signaling 4) is perhaps 
the most replicated specific transcriptional change in schizophrenia. 
The use of tissue samples, such as blood, from living patients is a route to practical 
biomarker identification. However, this demands that peripheral gene expression profiles 
reflect those in the brain and, to date, there are conflicting reports on this matter (Ref. 
95, 96, 97, 98). Similarly, many studies have examined gene expression changes in 
genetic or therapeutic models of schizophrenia in cell lines or transgenic mouse models 
(Ref. 99, 100, 101). These studies tend to yield relatively robust findings and may prove 
to be a starting point for biological hypotheses that may be confirmed in post mortem 
tissue. 
A new addition to microarray studies is the search for changes in the endogenous 
microRNA species that bind gene regulatory sequences and are thought to co-ordinate 
global transcriptional responses. Human post-mortem studies have been recently 
summarised (Ref. 102, 103) and the findings indicate a number of specific miRNAs 
associated with schizophrenia that implicate, via shared ontology of their targets, 
neurodevelopmental and neurotransmitter pathways in disease pathology. A role for 
perturbed miRNA signalling in schizophrenia is further suggested by the presence of the 
DGCR8 gene in the 22q11.2 VCFS deletion region: this gene encodes a component of 
the miRNA processing complex. 
 
Proteomic studies 
The schizophrenic proteome has also been explored for its biomarker potential; again 
focussing on clinically accessible tissue samples such as blood serum and cerebrospinal 
fluid (CSF) (Ref. 104, 105). The studies show good consistency and often overlap with 
existing genetic findings as recently reviewed in detail (Ref. 105). Alterations in the 
abundance of proteins with roles in metabolic function, particularly glycolysis, (ENO1, 
ENO2, ALDOC, PGAM1, TPI1, and LDHB) and the cytoskeleton (INA, NEFL, and 
SEPT3) are particularly frequently observed associated with schizophrenia (Ref. 106, 
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107, 108, 109, 110). A recent study found that stimulation of peripheral blood 
mononuclear cells from schizophrenia patients resulted in significant increases in 
glycolytic enzyme expression in comparison to the same procedure in healthy controls 
(Ref. 111). 
One specific finding merits further discussion. CSF up-regulation of the secreted factor 
VGF has been shown in cases of schizophrenia and depression, even before 
therapeutic drug use (Ref. 112, 113). Independently, VGF has been implicated in 
metabolic control and appears to mediate the anti-depressant actions of exercise via 
increased hippocampal neurogenesis (Ref. 114, 115, 116, 117). We have recently 
demonstrated that the VGF gene is a target of the NPAS3 transcription factor (Ref. 118). 
 
Metabonomic studies 
Perhaps the most recently developed tool applied to schizophrenia is based on the 
large-scale biochemical analysis of tissue from patients or transgenic mouse models – 
usually achieved through a combination of chromatography and high-resolution mass 
spectrometry (Ref. 119). Improvements in resolution mean that several hundred 
molecular species can be identified, depending on the precise extraction conditions and 
separation parameters. Biosynthetic pathway flux, redox balance, cellular energy state, 
neurotransmitter abundance, and membrane composition can all be assessed. Hence, 
the resulting data are of a different flavour to those described above; providing a 
snapshot of the homoeostatic interactions between genome-directed enzyme 
expression, disease pathology, and environmental factors. The results of metabonomic 
studies of schizophrenia have been reviewed previously (Ref. 120, 121) and frequently 
include disruptions to three biological processes. Firstly, schizophrenia alters brain lipid 
composition, for example, phosphatidylethanolamine and phosphotidylcholine (omega-6 
forms, in particular) – a state that is reversible with antipsychotic use (Ref. 122, 123, 
124, 125). This interaction with medication is further indicated by the general and 
specific changes in lipid pathway transcriptomics induced by a wide spectrum of 
neuroleptics (Ref. 101). Secondly, schizophrenia, like other CNS disorders such as 
Parkinson’s, Alzheimer’s and Multiple Sclerosis, is associated with metabolic changes 
consistent with an imbalance in redox state and/or oxidative stress (Ref. 126, 127, 128). 
Notably, the free radical scavenger glutathione appears to be reproducibly decreased 
(Ref. 129, 130) and mirrored in the observed genomic deletions of Glutathione S-
Transferase genes in schizophrenia (Ref. 131). Thirdly, and perhaps closely related to 
 11 
these defective oxidative processes, are the reported deficiencies in glucose utilisation 
(Ref. 132) and energy production that point to perturbed anaerobic glycolysis and 
mitochondrial oxidative respiration (Ref. 133, 134). The role of glucose metabolism is 
especially relevant in the context of the increased risk of metabolic syndrome/type II 
diabetes in schizophrenia. While this can often be linked with antipsychotic side-effects, 
there is good evidence for inherent deficits of glucose metabolism in drug naïve patients 
(Ref. 135, 136). Oxidative damage to the mitochondrial genome has been frequently 
reported in schizophrenia, highlighting this organelle as a focus of pathology (Ref. 137). 
Additionally, mitochondrial morphology and subcellular distribution are known to be 
regulated by DISC1 and its interactors such as IMMT/mitofilin (Ref. 138, 139, 140). The 
metabolomic approach may help expand transgenic animal model phenotyping. We 
recently demonstrated that Npas3 knockout brain tissue has specific disturbances of the 
NAD+ redox intermediate as well as components of the glucose and pentose phosphate 
metabolic pathways: a finding that was supported by in vitro analysis of this transcription 
factor’s gene targets (Ref. 118). 
 
Established candidate genes 
Specific gene-hunting methods have led to the discovery of several strong candidate 
schizophrenia genes. Three of these are briefly summarised here: DTNBP1 
(dystrobrevin-binding protein 1/dysbindin) (Ref. 141), NRG1 (neuregulin) (Ref. 142) and 
DISC1 (disrupted in schizophrenia) (Ref. 61). Each has spawned a dedicated research 
field employing cell biology and transgenic mouse modelling to link gene function to 
disease. 
Dysbindin is known to interact with component proteins of the biogenesis of lysosome-
related organelles complex 1 (BLOC-1) and dystrophin associated protein complex 
(DPC) (Ref. 143). A number of directly interacting proteins in these complexes (e.g., 
CMYA5) have also been independently linked with risk of schizophrenia. Other 
candidate disease proteins such as NRXN1 and LARGE are indirectly associated with 
the DPC. 
Neuregulin encodes multiple isoforms of a growth factor with known roles in both 
neuronal (inhibitory interneuron) and glial cell function. NRG1 isoform Type IV has 
particular relevance to schizophrenia as its promoter lies close to the SNP with strongest 
genetic association with illness. Neuregulin signals through the ErbB4 receptor that has 
also been associated with schizophrenia (Ref. 144, 145) 
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In the ten years since the discovery of DISC1, work on the gene has moved from genetic 
risk confirmation to extrapolation of function by mapping protein interactors (Ref. 60, 
146) and, finally, onto pathological and behavioural studies in transgenic mouse models. 
Figure 1 summarises the predominant cellular roles of DISC1 by presenting the multiple 
protein interactions that have been described at the nucleus, mitochondrion, 
centrosome, growth cone and synapse. One particularly important DISC1 function can 
be summarised as the harnessing of the cytoskeleton for intracellular trafficking, cellular 
movement and axonal extension which, in turn, contributes to structural brain 
development and clinical manifestations. 
 
Figure 1 legend here to maintain reference numbering 
The function of DISC1 has been defined by its protein interactions and has generated 
deep insights into the molecular basis of neurodevelopmental failures central to the 
aetiology of schizophrenia. DISC1 (yellow) is shown at two locations in the centre of the 
diagram and its interactors lead to various outputs located at the top and bottom. In the 
case of the centrosome, cytoskeleton and axonal growth/migration, all three can be 
considered different aspects of the same neurodevelopmental pathway. The data (only a 
subset of the total) have been assembled from general (Ref. 147, 148, 149, 150, 151, 
152, 153, 154) and specific protein interaction papers. DISC1 interacts with 
KALRN/HAPIP (Ref. 155), DBZ/ZNF365A (Ref. 147, 148), the NDE1 complex (Ref. 156, 
157), BBS4 and PCM1 (Ref. 158), PDE4B (Ref. 66), FEZ1 (Ref. 151), CAMD1 (Ref. 
159), GIRDIN and AKT (Ref. 160, 161), KIF5A and YHWAE/14-3-3  (Ref. 162, 163, 
164), DIXDC1 (Ref. 165), and IMMT/mitofilin (Ref. 140). 
 
 
Functional paradigms in schizophrenia 
 
Cellular trends 
As the schizophrenia risk gene/protein sets accumulate and resolve, they are assessed 
for statistically significant over-representation of certain ontologies. This convergence of 
processes and pathways thus defines likely biological causes of schizophrenia. The 
genomic dissection of autistic spectrum disorders (ASD), accelerated by its substantial 
cytogenetic component, has led the way in this regard, with at least three clear functional 
asymptotes discovered – that of the structure and function of the synapse, axonal 
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insulation, and the mTOR pathway (Ref. 166, 167). In Figure 2, a model neuron is 
shown together with a subset of the genes/proteins detailed within this review grouped 
according to their typical functions/subcellular locations. Does it permit new insights 
beyond the banal fact that synapses, axons and dendrites are all important in 
schizophrenia aetiology? The concentrated cytoskeletal and mitochondrial/metabolic 
links may be the most revealing aspects. The former is in line with the action of the 
DISC1 complex detailed above. Thus we can place the cytoskeletal processes of  
intracellular trafficking as well as the dynamic migration of neurons and axonal extension 
during developmental at the forefront of aetiological processes linked with schizophrenia. 
The density of proteins involved in glycolysis and mitochondrial function is an indication 
of the perturbed state of brain energy regulation in schizophrenia. 
In summary, a variety of techniques persuasively suggest that deficiencies of the 
synapse, cytoskeleton, cell adhesion, metabolism, and oligodendrocyte function are key 
factors underlying schizophrenia. 
 
The immune system 
As studies of schizophrenia transition from the cellular to organism level, several 
biological processes become apparent including inflammation and adult neurogenesis. 
Epidemiological data have long supported an immune component to schizophrenia. The 
increased risk of schizophrenia due to habitation in an urban environment (Ref. 168) 
may be explained by increased exposure to infectious disease (Ref. 169). The proposed 
mechanism is via effects of maternal infections during pregnancy impinging on the 
formation of the foetal brain during critical neurodevelopmental stages. Specific 
infections, such as the cat-borne Toxoplasma gondii parasite, have been repeatedly 
associated with risk of schizophrenia and linked to behavioural and cognitive 
performance changes (Ref. 170, 171). At the molecular level, there is evidence for 
increased levels of inflammatory markers (e.g., interleukins) in the brains of those 
diagnosed with schizophrenia. Interleukin administration during rodent development can 
induce schizophrenia-like phenotypes (Ref. 172). Targeting these inflammatory 
processes in schizophrenia – for example, by reducing prostaglandin E2 production with 
the non-steroidal anti-inflammatory drug, aspirin (Ref. 173) – appears to be a useful 
adjunct to conventional antipsychotic treatment. 
En masse analysis of GWAS data sets has described a relationship between 
schizophrenia and bipolar disorder but clearly distances them both from the core group 
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of common, complex genetic disorders known to share an autoimmune component (e.g., 
rheumatoid arthritis - RA, Crohn’s disease - CD, multiple sclerosis – MS, and types I or II 
diabetes – T1D/T2D) (Ref. 25). Nevertheless, the association between schizophrenia 
and the MHC region on chromosome 6 suggests a link may exist. A recent analysis of 
GWAS overlaps among the autoimmune disorders (Ref. 174) identified genes with 
considerable relevance to schizophrenia. For example, NRXN1 (a shared risk factor for 
RA, CD and MS), TRIM27 (RA, CD and T1D) - and with less statistical significance for 
overlap - ZNF804A (RA, T1D), CSMD1 (RA, MS), and ZDHHC8 (RA, T2D), have also 
been identified in the schizophrenia GWAS and CNV literature. 
Immunostimulation of mice using compounds such as lipopolysaccharide or polyI:C has 
recently been used in an attempt to model such gene x environment interactions. Both 
postnatal and in utero treatments of polyI:C have been employed in mice over-
expressing a dominant-negative mutant form of the human DISC1 protein (Ref. 175, 
176, 177). For both time-points, combining immunostimulation and mutant DISC1 over-
expression resulted in significantly greater phenotypic consequences than treatment or 
over-expression alone. The effects were diverse, ranging from increased 
anxiety/depression, altered social interaction, behavioural paradigm performance 
changes, memory deficits, altered interleukin production (IL-1 up, IL-5 down), reduced 
HPA axis activation in stressful conditions, reduction in DISC1-specific enlargement of 
lateral ventricles, reduction in parvalbumin-expressing interneuron number, and reduced 
dendritic spine density. These are important hypothesis-driven experiments that expose 
the breadth of responses to gene-environment interaction but, as yet, do not fully reveal 
whether these effects are independent (additive risk) or mechanistically synergistic (a 
role for DISC1 in immunomodulation). In terms of linking DISC1 to immune response, it 
is intriguing to note that one of its protein interactors, ZNF365 (DBZ/KIAA0844), is also a 
key candidate for Crohn’s disease (Ref. 178) and breast cancer (Ref. 179), both with 
immune components to their aetiologies. 
Aside from proinflammatory pathways, new interest in the actions of the innate and 
adaptive immune systems in the central nervous system has been sparked by the 
realisation of the extent to which both MHCI and complement cascade proteins such as 
C3 contribute to synapse pruning during development (for example, the visual system in 
the dorsolateral geniculate nucleus) and in neurodegenerative disorders (Ref. 180). This 
is particularly intriguing when it is considered that excessive synaptic pruning within the 
adolescent pre-frontal cortex may directly precede and contribute to the onset of 
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schizophrenia (Ref. 181, 182, 183). The protein CSMD1, discussed above, appears to 
play a role in complement pathway regulation. 
 
Adult neurogenesis 
Structural brain imaging studies support a neurodevelopmental model of schizophrenia 
(Ref. 3). This model is physically manifest at the levels of proliferation, differentiation and 
migration of neurons during the embryonic formation of the cortex and, later, 
recapitulated as the addition of new granule cells to the dentate gyrus region of the 
hippocampus in adulthood (Ref. 184, 185). At the molecular level, protein interactors 
such as DISC1, NDE1 and PAFAH1B1, for example, are known to be vital participants in 
both the embryonic and adult processes. Moreover, both processes involve a defined 
layer of stem cells located within the subventricular zone (SVZ) or subgranular zone 
(SGZ) that generate a neuronal progenitor population dividing to produce daughter cells 
committed to a neural fate. Importantly, the process doesn’t begin and end with this 
proliferation; in adult neurogenesis, only a proportion of the new neurons successfully 
differentiate, migrate and integrate permanently into the existing neuronal architecture – 
the remainder apoptose.  
Post-mortem studies showing that adult neurogenesis is attenuated in schizophrenia 
(Ref. 186) together with evidence that it is improved by antipsychotic treatment have 
sparked enormous interest in it as a potential pathology that may also reflect defects in 
embryonic neurodevelopment (Ref. 185). Dentate gyrus granule cells form one of the 
component synaptic junctions – mossy fibre synapses - in the hippocampal trisynaptic 
circuitry that contribute to the long-term activity-dependent synaptic plasticity changes 
(long-term potentiation - LTP) thought to underlie learning and memory. Therefore 
neurogenesis, via effects on LTP, has the potential to contribute to some of the cognitive 
aspects of schizophrenia, although evidence to support this is currently incomplete (Ref. 
187). 
The rate of neurogenesis in transgenic mouse models of schizophrenia (as measured by 
the incorporation of nucleotide analogues into the genomic DNA of dividing cells) 
provides an attractive means to quantify effects of the single genetic defect and correlate 
this with behavioural and cognitive deficits. However, adult neurogenesis does not 
measure up perfectly as a causative pathology in schizophrenia. Firstly, neurogenesis 
declines steeply with age in rodents and humans which is at odds with the course of 
schizophrenia. Secondly, neurogenic proliferation is a highly reactive phenomenon. 
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Many stimuli seem able to trigger it including hypoxia, aerobic exercise, environmental 
stimulation, sex hormones, and seizures. Thirdly, it is somewhat disconcerting to see it 
touted as an important pathology in Alzheimer’s (Ref. 188) and other forms of 
neurodegeneration (Ref. 189, 190, 191, 192). In the light of these conflicting properties, 
one pragmatic stance might be that levels of adult hippocampal neurogenesis provide a 
useful barometer of neurodevelopmental competence, general cognitive activity and 
‘health status’ of the brain – rather than a specific risk factor for schizophrenia.  
Transgenic mouse models of schizophrenia have been vital in driving the association 
between neurogenesis and schizophrenia. Multiple strains with Disc1 dysfunction have 
comprehensively dissected the gene’s role in embryonic and adult neurogenesis 
revealing participation in both the proliferative and migration/maturation stages (Ref. 
160, 161, 193, 194, 195, 196, 197, 198, 199, 200, 201). 
Mice lacking the Npas3 gene also display cognitive, behavioural and 
neurodevelopmental phenotypes (including adult neurogenesis deficiency) consistent 
with a model for human psychiatric illness (Ref. 202, 203, 204). A recent paper (Ref. 
205) described an in vivo screen for small molecules that could reverse the 
neurogenesis phenotype in Npas3 mutant mice. One molecule that achieved this, P7C3, 
helped determine that the Npas3 neurogenesis failure was due to increased levels of 
apoptotic death among newly formed neurons, rather than defective proliferation. As 
electro-convulsive stimulation of Npas3 knockout mice also restores neurogenesis, it 
might be speculated that Npas3 acts as a survival checkpoint: determining whether new 
neurons are registering ‘activity’ consistent with appropriate integration into dentate 
gyrus circuitry. Intriguingly, the Npas3 knockout deficits appear to be a consequence of 
mitochondrial fragility – in line with the metabolic defects described earlier – making this 
gene a point of convergence for glucose metabolism and neurodevelopmental risk 
mechanisms. 
 
Outstanding issues in schizophrenia biology 
 
The recent progress in the study of schizophrenia is beginning to place the disorder 
within a robust framework of key biological processes. However, three outstanding 
issues have emerged, and tackling them may greatly facilitate the practical application of 
this new-found knowledge. 
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Personal schizophrenia 
There is a need to quantify genetic risk at the level of the individual. GWAS identifies 
common genetic variants contributing to population risk of psychiatric illness. It can be 
thought of as utilising a ‘horizontal’ approach in which averaged allele frequencies are 
compared between cohorts of cases and healthy controls. This is in contrast to ‘vertical’ 
studies such as CNV detection and exome resequencing which define the genetic status 
of the individual. The consequence of this distinction is that GWAS variants are not 
studied in their genomic context – as an additive (or even multiplicative) contribution to 
an individual’s mutational load. The horizontal approach benefits considerably from 
statistical power but the vertical approach comes closer to the clinical goal of predictive 
testing for disease status and effective treatment. With common genetic variation 
predicted to act via transcriptional regulation, there is now an opportunity to combine 
genomic and transcriptomic datasets to reveal those ‘expression quantitative trait loci’ 
(eQTLs) with greatest relevance to schizophrenia aetiology in the individual (Ref. 206, 
207, 208, 209, 210). Such studies – already applied to DISC1 pathway biology (Ref. 
211), and supported by a very recent proof-of-concept study (Ref. 212) - will require the 
correlation of CNS-relevant expression profiles from multiple individuals diagnosed with 
schizophrenia with their genome-wide SNP genotypes. The generation and neuronal 
differentiation of patient induced pluripotent stem (iPS) cell lines may provide the 
appropriate material to make this approach feasible (Ref. 213, 214, 215).  
 
Overlapping aetiologies 
The estimate of a 50% genetic overlap between schizophrenia and bipolar and its further 
biological relationships with ASD, epilepsy and mental retardation requires 
reassessment of both simple models of neuropsychiatric disorder classification and 
single-process aetiologies. It may also force a categorisation of risk factors according to 
their mode and site of action. If it is found that much of the shared genetic variation is 
present in the neurodevelopmental gene fraction then a model based on a ‘fragile brain’ 
endophenotype might be constructive. Such a model would be consistent with the 
substantial genetic heterogeneity observed as it would just require an initial generalised 
deficiency in brain function/connectivity. A secondary hit by other genetic factors or the 
environment would then produce diagnosis-specific pathologies (Figure 3). Applying a 
crude computer analogy, the neurodevelopmental failures may cause relatively non-
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specific defects in hardware while disease-specific processes target specific routines in 
the software.  
 
Cause and effect in schizophrenia 
An important issue is how to define the point of action of any biological process linked 
with schizophrenia (Figure 3). Are we able to distinguish those biological pathways that 
are bona fide primary causes of schizophrenia from those that are the downstream 
reaction to, or homeostatic consequences of, schizophrenia or environmental risk 
factors? This may have pertinence for diagnosis and treatment. Genetic or molecular 
factors identified through the methods outlined above might reflect patient-specific 
responses to a primary deficit just as much as the primary deficit itself, and so an early-
life diagnostic test might be better aimed at the latter. Similarly, therapeutic drugs may 
be best targeted to the root causes or downstream consequences of disease (or both 
(Ref. 173)). In such a model, where do current antipsychotics act? As one moves up the 
biological hierarchy from gene to cell to organ and then individual, reactive processes 
are likely to be more prevalent (Figure 3). The process of inflammatory response would 
perhaps fall into the reactive category whereas cytoskeleton function, for example, might 
be considered causative. Embryonic neurogenesis would be causative, adult 
neurogenesis potentially reactive. This distinction would be mirrored in the discovery 
arena too. Genomic strategies are likely to reflect cause (although there will clearly be a 
genetic component to reaction) whereas other ‘-omics’ would be increasingly influenced 
by environment and disease state. The skewed distribution of evidence for metabolic 
disturbance in the upper part of the hierarchy, as detailed above, suggests it plays more 
of a reactive or secondary role – however, the Npas3 findings argue otherwise. Perhaps 
the detection of cell autonomous defects, a possible corollary of causation, may be 
ideally suited to resolve the cause-effect dilemma. Again, the study of patient iPS cells 
might be invaluable in this regard. 
A biological definition of the causes of schizophrenia is now a realistic, albeit 
challenging, goal. Its potential to influence therapeutic strategies, diagnostic methods 
and social acceptance of those diagnosed would be considerable: more than justifying 
the time, effort, cost and frustration involved in its formation.  
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Figure legends 
 
Figure 1 
The function of DISC1 has been defined by its protein interactions and has generated 
deep insights into the molecular basis of neurodevelopmental failures central to the 
aetiology of schizophrenia. DISC1 (yellow) is shown at two locations in the centre of the 
diagram and its interactors lead to various outputs located at the top and bottom. In the 
case of the centrosome, cytoskeleton and axonal growth/migration, all three can be 
considered different aspects of the same neurodevelopmental pathway. The data (only a 
subset of the total) have been assembled from general (Ref. 147, 148, 149, 150, 151, 
152, 153, 154) and specific protein interaction papers. DISC1 interacts with 
KALRN/HAPIP (Ref. 155), DBZ/ZNF365A (Ref. 147, 148), the NDE1 complex (Ref. 156, 
157), BBS4 and PCM1 (Ref. 158), PDE4B (Ref. 66), FEZ1 (Ref. 151), CAMD1 (Ref. 
159), GIRDIN and AKT (Ref. 160, 161), KIF5A and YHWAE/14-3-3  (Ref. 162, 163, 
164), DIXDC1 (Ref. 165), and IMMT/mitofilin (Ref. 140). 
 
Figure 2 
Convergent locations and actions of genes/proteins implicated in risk of schizophrenia 
from multiple discovery approaches. Neuron adapted from a Wikimedia Commons 
image (http://commons.wikimedia.org/wiki/File:Complete_neuron_cell_diagram_en.svg). 
 
Figure 3 
Models of schizophrenia biology and analysis. In this speculative representation, 
distinctions between biological cause and effect are presented from left to right. These 
highlight primary deficits and reactionary responses in schizophrenia, the specific stages 
of biological processes that might be involved, the progression from general mental 
illness susceptibility to specific diagnoses, and the competence of commonly employed 
investigative techniques to resolve these aspects. ‘G X E’ indicates the combined effect 
of genes and environment on risk. 
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Further reading 
 
http://www.schizophreniaforum.org/ 
The Schizophrenia Research Forum contains up-to-date news and views on the 
progress of basic and clinical research into schizophrenia. 
 
http://www.schizophrenia.com/index.php 
A website much more directed towards informing those diagnosed with schizophrenia 
together with their families and carers. 
